Metastatic Cancer Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Enrolling by invitation
  • Melanoma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2022-04-07
    Apr 7, 2022
    E
    Completed
    • Advanced Cancer
    • +5 more
    • Los Angeles, California
    • +7 more
    2022-04-07
    Apr 7, 2022
    B
    Recruiting
    • Malignant Neoplasms
    • Metastatic Cancer
    • Shanghai, Shanghai, China
    • +4 more
    2022-04-05
    Apr 5, 2022
    M
    Recruiting
    • Metastatic Cancer
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-03-31
    Mar 31, 2022
    M
    Active, not recruiting
    • Advanced Cancer
    • +4 more
    • Saint Louis, Missouri
    • +3 more
    2022-04-04
    Apr 4, 2022
    M
    Recruiting
    • Patient Reported Outcome Measures
    • +7 more
    • Observational Cohort
    • Boston, Massachusetts
      Massachusetts General Hospital
    2022-04-04
    Apr 4, 2022
    L
    Recruiting
    • Metastatic Cancer
    • Stereotactic ablative radiotherapy - Level 1
    • +4 more
    • London, Ontario, Canada
      London Health Sciences Centre - London Regional Cancer Program
    2022-04-04
    Apr 4, 2022
    C
    Recruiting
    • Advanced Gastrointestinal Stromal Tumors
    • Metastatic Cancer
    • CGT9486 plus sunitinib
    • +2 more
    • Duarte, California
    • +6 more
    2022-03-31
    Mar 31, 2022
    T
    Active, not recruiting
    • Solid Tumor
    • Metastatic Cancer
    • Birmingham, Alabama
    • +3 more
    2022-03-31
    Mar 31, 2022
    T
    Not yet recruiting
    • Breast Cancer Invasive
    • +2 more
    • Surgery
    • +2 more
    • Amsterdam, Netherlands
      Antoni van Leeuwenhoek
    2022-03-21
    Mar 21, 2022
    P
    Recruiting
    • Metastatic Cancer
    • Epithelial Tumor
    • NG-641 in combination with Nivolumab
    • Santa Monica, California
    • +2 more
    2022-03-16
    Mar 16, 2022
    F
    Recruiting
    • Advanced Cancer
    • Metastatic Cancer
    • New Haven, Connecticut
    • +7 more
    2022-03-29
    Mar 29, 2022
    F
    Recruiting
    • Advanced Cancer
    • Metastatic Cancer
    • Pamplona, Navarra, Spain
    • +5 more
    2022-03-29
    Mar 29, 2022
    G
    Recruiting
    • Hepatocellular Carcinoma
    • Metastatic Cancer
    • GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
    • Makati City, Philippines
    • +3 more
    2022-03-14
    Mar 14, 2022
    I
    Active, not recruiting
    • Locally Advanced Solid Tumor
    • +2 more
    • PD-L1 t-haNK
    • El Segundo, California
      Chan Soon-Shiong Institute for Medicine
    2022-03-28
    Mar 28, 2022
    H
    Recruiting
    • Sarcoma, Synovial
    • +8 more
    • CYCLOPHOSPHAMIDE and FLUDARABIN
    • +3 more
    • Jerusalem, Israel
      Hadassah Medical Organization
    2022-03-15
    Mar 15, 2022
    A
    Not yet recruiting
    • Advanced Solid Tumor
    • Metastatic Cancer
    • Miranda, New South Wales, Australia
    • +2 more
    2022-03-21
    Mar 21, 2022
    A
    Recruiting
    • Metastatic Cancer
    • +2 more
    • ASP9801
    • Pembrolizumab
    • Birmingham, Alabama
    • +24 more
    2022-03-20
    Mar 20, 2022
    B
    Not yet recruiting
    • Head and Neck Cancer
    • +4 more
    • Ozuriftamab Vedotin
    • PD-1 inhibitor
    • (no location specified)
    2022-03-08
    Mar 8, 2022
    G
    Recruiting
    • Solid Tumor
    • +3 more
    • Los Angeles, California
    • +5 more
    2022-03-07
    Mar 7, 2022
    C
    Recruiting
    • Head and Neck Cancer
    • +2 more
    • Standard arm
    • Experimental arm
    • Montréal, Quebec, Canada
      Centre Hospitalier de l'Université de Montréal
    2022-03-06
    Mar 6, 2022